The expression of retinal cell markers in human retinal pigment epithelial cells and their augmentation by the synthetic retinoid fenretinide

Amanda-Jayne Carr,1,2 Anthony A. Vugler,1,2 Lu Yu,1 Maayan Semo,2 Pete Coffey,2 Stephen E. Moss,1 John Greenwood1

(The first two authors contributed equally to this work.)

1Department of Cell Biology, UCL Institute of Ophthalmology, University College London, London, UK; 2Department of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, University College London, London, UK

Purpose: In several species the retinal pigment epithelium (RPE) has the potential to transdifferentiate into retinal cells to regenerate functional retinal tissue after injury. However, this capacity for regeneration is lost in mammals. The synthetic retinoic acid derivative, fenretinide \([N(4\text{-}\text{hydroxyphenyl}) \text{retinamide}]\), induces a neuronal-like phenotype in the human adult retinal pigment epithelial cell line (ARPE-19). These changes are characterized by the appearance of neural-like processes and the expression of neuronal markers not normally associated with RPE cells. Here we assess whether fenretinide can induce a neuroretinal cell phenotype in ARPE-19 cells, by examining retinal cell marker expression.

Methods: ARPE-19 cells were treated daily with culture medium containing either 3 μM fenretinide or dimethyl sulfoxide as a control for 7 days. Cells were processed for immunocytochemistry, western blotting, and for analysis by PCR to examine the expression of a panel of RPE, neural, and retinal-associated cellular markers, including classical and non-canonical opsins.

Results: Treatment with fenretinide for 7 days induced the formation of neuronal-like processes in ARPE-19 cells. Fenretinide induced the expression of the cone long wavelength sensitive opsin (OPN1lw) but not rhodopsin (RHO), while decreasing the expression of RPE cell markers. Many of the neuronal and retinal specific markers examined were expressed in both control and fenretinide treated cells, including those involved in photoreceptor cell development and the multipotency of neural retinal progenitor cells. Interestingly, ARPE-19 cells also expressed both photoreceptor specific and non-specific canonical opsins.

Conclusions: The expression of retinal-associated markers and loss of RPE cell markers in control ARPE-19 cells suggests that these cells might have dedifferentiated from an RPE cell phenotype under standard culture conditions. The expression of molecules, such as the transcription factors paired box 6 gene (PAX6), sex determining region Y-box 2 (SOX2), cone-rod homeobox (CRX), and neural retina leucine zipper (NRL), further implies that in culture these cells are predisposed toward a retinal progenitor-like state. The fenretinide-induced increase in photoreceptor cell markers, accompanied by a decrease in RPE cell markers, suggests that retinoids may play a role in the transdifferentiation of RPE cells. Importantly, our data show for the first time the expression of a vertebrate ciliary opsin (OPN1lw) and rhodopemeric-like opsin, opsin 4 (OPN4 also known as melanopsin) in a clonal cell line. Together these data suggest that ARPE-19 cells are primed for and possess the capacity to differentiate toward a retinal cell-like lineage.

The retinal pigment epithelium (RPE), located between the neurosensory retina and the choroid, is a monolayer of cells vital for the maintenance of photoreceptor cell function and integrity. The RPE also plays a critical part in the development of the retina [1] and in some species participates in the regeneration of functional neural retinal tissue after injury [2] through RPE cell dedifferentiation, proliferation, and redifferentiation into the cellular elements of the retina (a process termed transdifferentiation). Many mature amphibians, such as the salamander [3], newt [4,5], and \textit{Xenopus} [6], are capable of this process throughout their lives, while in birds it appears to be restricted to a limited period during embryonic eye development [7]. Mammals have lost the ability to regenerate the retina in vivo, although there is evidence to suggest that embryonic RPE cells transplanted into the adult eye are capable of forming retinal-like tissue [8] and that embryonic RPE cells are able to form a multilayered structure, expressing several retinal cell markers after treatment with basic fibroblast growth factor (bFGF) in culture [9].

To regenerate a complete retina, RPE cells must be able to transdifferentiate into several cell types. Analysis of cells from species where transdifferentiation has been shown to
occur has revealed that RPE cells are capable of differentiating into retinal ganglion, amacrine, photoreceptor, and glial cells [5,9-11], and lens [4]. Many factors have been shown to regulate the transdifferentiation of RPE cells into neural retina, including bFGF [11], insulin [12], neuroD [13], mitogen activated protein kinase extracellular signal related kinase (MEK) [14], and neurogenin [15]. Whereas transforming growth factor (TGF)-β-like molecules, such as activin, thought to be involved in RPE cell differentiation [16], have been shown to block regeneration of the retina from RPE [17].

Retinoic acid has been shown to induce the expression of retinal cell markers in ARPE-19 cells. ARPE-19 cells were seeded onto tissue culture inserts of Transwell® insert (Sigma-Aldrich) and the anterior lens capsule membrane attached to the plastic support. The insert was washed in Hanks Balanced Salt Solution containing 1% penicillin–streptomycin and tested for sterility before seeing. For each experiment, 1×10^5 cells/cm² were used. Cells were trypsinized and passaged onto 35-mm uncoated dishes and tissue culture flasks at a density of 2×10^5 cells/cm². The following day cells were washed and treated with low-serum medium containing DMEM/F-12 (1:1)+ GlutaMAX™ with 1% penicillin–streptomycin and 3% charcoal–dextran-treated FBS (Invitrogen, Paisley, UK). The immortalized RPE cell line hIRPE7 was also cultured in Ham's F-10 with 10% heat-inactivated FCS, 2 mM l-glutamine and 1% penicillin–streptomycin [29]. Cells were incubated at 37 °C with 5% CO₂. Cells were trypsinized and passaged onto 35-mm uncoated dishes and tissue culture flasks at a density of 2×10^5 cells/cm². The following day cells were washed and treated with low-serum medium containing 3 μM fenretinide (Tocris Bioscience, Bristol, UK) dissolved in DMSO (Sigma-Aldrich Company Ltd, Dorset, UK). This treatment protocol was repeated once a day for a further 6 days. All handling of fenretinide was performed under low-light conditions. Control cells were cultured under identical conditions in low-serum medium with the addition of an equivalent volume of DMSO (0.03% volume [v]/v) only. Phase contrast images and scanning electron micrographs were taken following 7 days of treatment.

For the porcine lens capsule membrane (PLC) experiments the lens capsule membrane was isolated from porcine eyes (Cheale Meats Ltd, Brentwood, UK). The polyclonal membrane was removed from a Corning® Transwell® insert (Sigma-Aldrich) and the anterior lens capsule membrane adhered to the remaining plastic support. The anterior lens capsule was carefully removed leaving the anterior lens capsule membrane attached to the plastic support. The insert was washed in Hanks Balanced Salt Solution containing 1% Penicillin-Streptomycin and tested for sterility before seeing. ARPE-19 cells were seeded onto tissue

METHODS

Cell culture: ARPE-19 cells (passage 22) and passage 2 human RPE cells (G.A. Limb, University College London, London, UK) were cultured in standard culture medium containing Dulbecco's Modified Eagle's Medium and Ham's F-12 Nutrient Mixture (DMEM/F12) mix (1:1)+ GlutaMAX™ with 1% penicillin–streptomycin and 10% fetal bovine serum (FBS; Invitrogen, Paisley, UK). The immortalized RPE cell line hIRPE7 was also cultured in Ham's F-10 with 10% heat-inactivated FCS, 2 mM l-glutamine and 1% penicillin–streptomycin [29]. It has previously been reported that retinoic acid has an effect on the differentiation of ARPE-19 cells, a spontaneously immortalized adult RPE-derived cell line, which has been widely used as a model system for the study of RPE cells in vitro [24]. For example, treatment with retinoic acid delays the appearance of RPE cell morphology and the expression of RPE-specific genes peropsin, RPE65 and 11-cis retinal dehydrogenase [25]. Furthermore, there is compelling evidence to suggest that ARPE-19 cells are capable of differentiating into neuronal-like cells after treatment with the synthetic analog of retinoic acid N-(4-hydroxyphenyl) retinamide (fenretinide) [26] or after pretreatment with a neural stem cell media followed by 10 days exposure to retinoic acid [27]. Following retinoid treatment, cells display neuronal-like elongated morphology with the extension of multiple processes. Cells were characterized by immunocytochemistry and found to express several neuronal cell markers after fenretinide treatment, including neurofilament medium polypeptide (NF-M), neurofilament heavy polypeptide (NF-H), calbindin 2 (CALB2), neural cell adhesion molecule and microtubule associated protein 5 [26-28]. Furthermore, NSE and PAX-6 expression dimethyl sulfoxide (DMSO)-treated cells, suggesting that ARPE-19 cells may act as a neuronal progenitor cell line [28].

These findings suggest that a mechanism to activate transdifferentiation toward neural cells might exist, at least in part, in human RPE cells and raises the possibility that RPE could, with the appropriate manipulation, be induced to produce new retinal cell types, replacing those lost as a result of degenerative disease. Although Amemiya et al. were unable to induce the expression of the retinal-associated cell markers with retinoic acid using their protocol [27], the effects of the synthetic analog of retinoic acid, fenretinide, on RPE differentiation toward a neuroretinal cell fate have yet to be examined. In this study we have used reverse transcriptase PCR (RT–PCR), real-time quantitative PCR (Q-PCR), immunocytochemistry, and western blot analysis to examine the effects of fenretinide on the expression of retinal cell markers in ARPE-19 cells.
culture plastic or PLC and treated with DMSO or fenretinide, as described above.

Reverse transcriptase PCR: Flasks of fenretinide-treated and control cells were twice washed in 1 x Dulbecco’s phosphate-buffered saline (2.7 mM KCl, 1.47 mM KH₂PO₄, 8.1 mM NaCl and 50.5 mM Na₂HPO₄ - PAA Laboratories Ltd., Yeovil, UK). TRIZol reagent (Invitrogen) was added to the flasks and cells lysed by trituration. RNA was isolated with chloroform induced phase separation and precipitated using isopropanol as instructed by the manufacturers. The RNA was treated with RQ1-RNase-free DNase (Promega, Southampton, UK) to remove any contaminating DNA. First-strand cDNA synthesis was performed on 3 μg of total RNA, using Superscript III Reverse Transcriptase with an oligo-(dT)20 primer (Invitrogen) at 50 °C, according to the manufacturer’s protocol. A reaction containing no reverse transcriptase was also prepared for each RNA sample as a control (-RT). Following cDNA synthesis all reactions were treated with RNase H (Invitrogen) to degrade the RNA template. PCR was performed on the first-strand cDNA synthesis reaction products, using GoTaq polymerase (Promega) according to the manufacturer’s protocol with gene-specific primers (synthesized by Eurofins MWG Operon, Ebersberg, Germany) described in Table 1. The PCR cycling parameters consisted of an initial denaturation step at 95 °C for 2 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at primer melting temperature minus 3 °C for 30 s and extension at 72 °C for 30 s, followed by a final extension step at 72 °C for 5 min. PCR products were separated on a 2% agarose gel and visualized using ethidium bromide. A no template water PCR control was included for each primer set.

Real-time quantitative PCR: cDNA was prepared from ARPE-19 cells as described above, and quantitative PCR performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Warrington, Cheshire, UK). Triplicate PCR reactions were prepared using 1 μl cDNA with Power SYBR Green PCR master mix (Applied Biosystems) and 0.2 μM of gene-specific primer (Eurofins MWG Operon) in a total volume of 25 μl. Primer sequences are contained in Table 1. Data were analyzed using SDS 2.2.2 (Applied Biosystems), and raw fluorescence data were exported into the DART–PCR spreadsheet (version 1.0) [31] to calculate relative gene expression normalized to the geometric mean of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-tubulin, and β-2-microglobulin. The specificity of all primers was assessed by gel electrophoresis of amplified products, band sequencing, and examination of the dissociation curve. The effects of fenretinide treatment on relative mRNA expression levels were assessed using SigmaStat 3.5 software (Systat Software, Inc., Chicago, IL). Two-tailed Student t tests were performed to compare expression in DMSO- and fenretinide-treated cells (n=4 per treatment group).

Immunocytochemistry: After 7 days of fenretinide or DMSO treatment, cells were washed with 0.1 M PBS (138 mM NaCl, 3.89 mM KCl, 2.13 mM KH₂PO₄, 8.16 mM Na₂HPO₄) fixed in 4% paraformaldehyde in PBS for 30 min at 4 °C and blocked for 2 h at 4 °C in a PBS solution containing 0.3% Triton X-100 (PBS-TX) and 5% normal donkey serum (NDS; Stratex Scientific Ltd., Newmarket, UK). Cells were then incubated overnight at 4 °C in PBS-TX containing 1% NDS with primary antibodies raised in mouse: RHO clone 4D2 (1:100, R Molday, University of British Columbia, Vancouver, Canada), KRT8 (1:2,000; Millipore, Watford, UK), CRX (1:1,000; Abnova, Heidelberg, Germany), NSE (1:50; Cymbus Biotechnology, Hampshire, UK), SYP (1:5,000; Millipore (UK) Ltd., Watford, UK), NF-M (1:1,000; Millipore UK) and rabbit: NF-H (1:5,000; Millipore UK), SCN1a (1:1,000; Millipore UK), PAX6 (1:300; Covance, Princeton, NJ), OPN1mw/hw (polycyclic antiserus JH492; J. Nathans, John Hopkins University, Baltimore, MD), CALB2 (1:1,000; Swant, Bellinzona, Switzerland), RCVN (1:1,000; Millipore UK), THY-1 (1:500; Source Bioscience AUTOGEN, Nottingham, UK), and OPN4 (antiserum, 1:10,000 and blocking peptide N-terminal [15AA NH2-MNPPSGPRPVSPTQ-COOH diluted at 100 ng/ml and pre-absorbed overnight at 4 °C before application] I. Provencio, University of Virginia, Charlottesville, VA). The following day cells were washed in PBS before incubation with appropriate combinations of FITC- or TRITC-conjugated antibodies (Stratech Scientific Ltd.) diluted at 1:200 in PBS-TX with 2% NDS. Cells were counterstained with 4’6-diamindino-2-phenylindole dihydrochloride (Sigma-Aldrich), washed in PBS and mounted in Vectorshield (Vector Laboratories Ltd., Peterborough, UK). Staining was imaged and analyzed using a Zeiss 510 confocal microscope with LSM Image Browser software (Joel (UK) Ltd., Welwyn Garden City, UK). As a control for the specificity of secondary antibodies, primary antibodies were omitted in some dishes.

Western blot analysis: Flasks of fenretinide- and control DMSO-treated cells were placed on ice, washed twice in cold 1X Dulbecco’s phosphate-buffered saline and harvested by scraping in lysis buffer (10 mM HEPES, 1% Triton X-100, 150 mM KCl, 1 mM PMSF, 10 ng/ml leupeptin, 1 mM dithiothereitol (DTT), 50 ng/ml aprotonin, 10 mM NaF, 100 μM sodium vanadate). The solutions were mixed at 4 °C for 30 min on a tube rotator and centrifuged at 17,000 xg for 30 min. The aqueous supernatants were isolated and the protein concentration estimated using BioRad protein assay reagent (Biorad, Hemel Hempstead, UK). Samples were diluted 1:1 in Laemmli sample buffer and denatured at 95 °C for 5 min. Equal amounts of protein were separated by sodium dodecyl sulfate PAGE (SDS–PAGE) and transferred to Hybond-polyvinylidene fluoride (PVDF) membrane (GE Healthcare Life Sciences, Buckinghamshire, UK) by electrophoresis at 4 °C. Membranes were blocked at room temperature for 1 h in blocking solution containing 10% milk.
| mRNA   | Forward primer (5'-3') | Reverse primer (5'-3') | Accession number | Size | Tm-3 °C |
|--------|------------------------|------------------------|------------------|------|---------|
| **RT–PCR** |                        |                        |                  |      |         |
| Best1  | AGTGGCGCATGGAGGAGCGGAGG | GACACACGAGTGCAGTCTCA    | NM_004183.3      | 226  | 64      |
| Brn3   | AGCCACCACACATGCAAGCCAAG | AGCTAGGACGGAGACGAAAG    | NM_006237        | 101  | 57      |
| Calb2  | GCGGCTACATGGAGCAGCAT    | GCAGCAGAAGAGAGCTTGG     | NM_001740        | 232  | 56      |
| Crx    | AGAGGGGAGAGGAGGCAATCC   | GCAGGCTTGAGGGAGGAGAG    | NM_000554        | 236  | 58      |
| Gfap   | TCTGACCTCTTCCCCACCTTCTT | GCCTTCCAGGTCCTCAGTCT    | S40719           | 288  | 58      |
| Irbp   | TGGGACCTTGCACCTGCTCT    | TGGCCGCTGTGGCATTTC      | NM_002273        | 290  | 55      |
| Krt8   | AGGGCGGCAAGAGCACAGAAG   | CAGCTGAGGGAGGAGAGACAG   | NM_002903        | 282  | 56      |
| Nf-m   | TCGGTATGTTTGTGTGTGTC    | TGGGCTGTGGGTGCTGTGTTT   | NM_001708        | 174  | 60      |
| Nf-h   | GAGCAGAGCTGAGGAGGAGG    | GGGTGGGTGAGGAGAGGAGG    | NM_000539        | 437  | 58      |
| Nse    | GACCTCCTTCCCCCTTCTTCT   | AACCTGAGGCACTTCACTC     | M22349           | 197  | 58      |
| Nrl    | AGAGGCGGACCTGTTCTGCTAG  | GCATCGGGATGAGGCTCTCT    | NM_006177        | 420  | 60      |
| Nr2e3  | TGCTTTCTCTCTGGCCACTC    | TTTCACCTGCCACCACTC      | NM_014249        | 274  | 56      |
| Opn1m/lw | GCCAGAGCCTGTTCTGCTAG   | GACACCTGAGGAGGAGGAGG    | NM_000513        | 211  | 60      |
| Opn1sw | GGTGACCTGCTGCTCTCTG    | TGGGGGTGAGGAGGAGGAGG    | NM_000539        | 437  | 58      |
| Rho    | TACAACAGGAGGAGGAGGAGG   | TCCTTGAGAGGAGGAGGAGG    | NM_000539        | 437  | 58      |
| Rtp    | CTTCTGGGCTCCTCTTTCCT   | AGGAGGAATGCTGATGCTC     | NM_014232        | 330  | 56      |
| Opn4   | GAAGCTGCTGAGTCTCCTGCTG | TAACTGTTCCAGGCTGCAA     | NM_00100015      | 2009 | 52      |
| Opn4(2) | TGCGGTGCTTATGCTCTCTT   | TGCCGAGCTATGCTCTCTCT    | NM_00100015      | 462  | 53      |
| Rvrm   | GGGAGGACCTGCTGCTTCTC   | CCGGTGAGGGAGGAGGAGG     | NM_002903        | 282  | 56      |
| Rgr    | CACGGGCTGAGGAGGAGGAGG   | CTCGGGGGAGGAGGAGGAGG    | NM_002921        | 338  | 60      |
| Rbhp   | GCCTCCGGAGAGGAGGAGG     | GGGTTGGGGTGGGGTTGG     | NM_000326        | 173  | 52      |
| Rh    | TCAAGGCTGAGCTCTCTCTC   | GTCTGAGAATCCTGGTA       | NM_000280        | 286  | 54      |
| Rpe65  | GCGGAGGAGGAGGAGGAGG    | GGCGAGCTGATGAGTTAAAAAC  | NM_000329        | 246  | 52      |
| Sag    | CTTGCTGAGGCTCTCTCTC    | TTTCTGGGCTGCTGCTGA     | NM_000541        | 195  | 52      |
| Silve  | GTGGTCTGAGGCTCTCTCTC   | GAGGGGGCTGATGAGTTAAAAAC| NM_006928        | 232  | 52      |
| Syp    | CGGTGAGGCTGCTGCTGCTC   | GTGGTGAGGCTGCTGCTC     | NM_003179        | 264  | 58      |
| Tbp    | GGAACGACCCAGAGCTTCTTCT | CCACTTTCTTCTTGCTTCTC   | NM_003194        | 177  | 52      |
| Thy-1  | GAGGGAGGAGGAGGAGGAGG   | CCGCAGAAGTTCCCTGAGA     | NM_002688        | 178  | 58      |
| Tubb3  | GCGAGATGCTAAGAGGAGGAGG| TTTAGAATCCCTGCTCTC      | NM_000608        | 420  | 60      |
| Ttr    | GACAAAGCAGCTCCTACAGC   | GACAAAGCAGCTCCTACAGC   | NM_000372        | 316  | 52      |
| **Q-PCR** |                        |                        |                  |      |         |
| Crx    | CCAAGCACTGAGGAGGAGG    | CCAAGCCTCGGCTGCTGCTC   | NM_000554        | 232  | 60      |
| Krt8   | AGGGAGGAGGAGGAGGAGG    | CGGTGAGGCTGCTGCTGCTC   | NM_002273        | 214  | 60      |
| Opn1m/lw | GCGGAGGAGGAGGAGGAGG   | GACCTGAGGAGGAGGAGG     | NM_000513        | 211  | 60      |
| Opn3   | CTGGTCTGAGGCTCTCTCTC   | AGGAGGAATGCTGCTGCTC    | NM_014232        | 330  | 56      |
| B2m    | TGGGTGATGATGATGAGGAGGAGG | AGATGTTGGAGGAGGAGGATGAAAC| NM_004048        | 100  | 60      |
| Gapdh  | CCGGAGGAGGAGGAGGAGG    | GGTCTTTATGAGGAGGAGGAGG | NM_002046        | 104  | 60      |
| Tubb   | AATCGGAGGAGGAGGAGGAGG | AAGAGGAGGAGGAGGAGG     | NM_178014        | 119  | 60      |

Primer sequences for amplification of human opsins, RPE, retinal and neuronal specific genes: class IV POU domain-containing transcription factor 1 (Brn3), Calbindin2 (Calb2), Cone rod homeobox (Crx), Glial fibrillary acidic protein (Gfap), Interphotoreceptor retinoid binding protein (Irbp), Neurofilament medium and heavy chains (Nf-m and Nf-h), Neuron specific enolase (Nse), Neural retinal1 leucine zipper (Nrl), retinal specific nuclear receptor (Nr2e3), Medium and long wave cone opsin (Opn1m/lw – primer pair amplifies both medium and long wavelength opsin due to highly conserved sequence), short wave cone opsin (Opn1sw), Rhodopsin (Rho), Encephalopsin (Opn3), Melanopsin (Opn4 – amplified in cells using nested PCR), Recoverin (Rvrm), Retinal G protein coupled receptor (Rgr), retina arrestin (Sag), Synaptophysin (Syp), Thy-1 cell surface antigen (Thy-1), b-3-tubulin (Tubb3), cytookeratin8 (Krt8), b-2-microglobulin (B2m) and Glyceraldehyde-3- phosphate dehydrogenase (Gapdh). The primer sequences used to amplify Crx for Q-PCR were taken from Peng and Chen 2007 [73].
RESULTS

Morphological changes induced by fenretinide: Initially we examined morphological changes associated with fenretinide treatment to ensure that the protocol used induced neuronal-like differentiation in the ARPE-19 cells. Similar to previous findings [26], cells cultured with DMSO appeared normal and grew to confluence (Figure 1A). In contrast, cells treated with 3 μM fenretinide for 7 days exhibited dramatic morphological changes characterized by an elongated appearance and the emergence of neuron-like processes (Figure 1B). Using scanning electron microscopy to resolve the morphology further, we observed structures reminiscent of neuronal cell processes (Figure 1C-E), and the presence of lamellae or ruffles at the “neurite” terminal (Figure 1F-G).

Analysis of gene expression in fenretinide-treated cells: To test for the presence of mRNA expression induced by fenretinide, we isolated RNA from fenretinide- or DMSO-treated ARPE-19 cells, synthesized cDNA, and used a panel of primers to amplify several photoreceptor-, neuroretinal-, neuronal-, and RPE-specific cell markers in equal amounts of cDNA by RT–PCR (Figure 2). Amplification products were observed in both DMSO- and fenretinide-treated cells for photoreceptor cell markers Rcrvn, Sag, and NR2e3 and neuroretinal cell markers Thy-1, Omp4, Calb2, and Gfap. Opm3 (also known as encephalopsin/panopsin), a non-canonical opsin expressed in the retina and other tissues throughout the body, was also present in both treatment groups. The neuronal cell markers Nf-m, Nf-h, Nse, Syp, and Tubb3 and the RPE cell markers Rlbp1, Krt8, Silv (also known as Pmel17), and Rrh were expressed in cells with and without fenretinide treatment, along with genes involved in retinal cell differentiation, Pax6, Crx, and Nr4. Interestingly, primers used to amplify both cone opsin sequences (Opm1lw and Opm1lw) produced a product only in the fenretinide-treated cells; sequencing of the amplicon revealed it to be Opm1lw. The retinal ganglion cell marker Brn3 was also amplified in fenretinide-treated cells only. Transcripts for the RPE cell markers Best1 and Tyr were not detected following fenretinide treatment, and we were unable to detect Rho, Opm1sw, Irbp, Rgr, or Rpe65 gene expression in either treatment group by RT–PCR.

To address quantitative changes in gene expression, we used Q-PCR to evaluate a select range of markers identified in the initial PCR screen (Figure 3). There was a significant increase in the expression of the Opm1lw transcript (p<0.05) after fenretinide treatment, with complete absence of amplification in the DMSO-treated cells. Opm3 and Krt8 were expressed in both treatment groups; however there was a significant decrease in mRNA expression of both genes following fenretinide treatment (p<0.05). Crx was amplified in both treatment groups with no significant difference in the levels of mRNA expression after fenretinide treatment (p=0.42). Rho expression was not quantifiable in either treatment group (data not shown).

Effect of fenretinide on protein expression in human retinal pigment epithelial cells: We next investigated the effects of 7 days treatment with DMSO or fenretinide in ARPE-19 cells on protein expression by immunocytochemistry. Several neuronal cell markers were expressed in ARPE-19 cells. The expression of NSE was enhanced by fenretinide treatment, particularly within the perinuclear region (Figure 4A). Both control and fenretinide-treated cells expressed SYP, with a wide distribution of staining throughout the control cells and clear staining throughout the dendrites after fenretinide treatment (Figure 4B). The voltage-gated Na+ channel SCN1a, which functions in the initiation and propagation of action potentials, was junctional in DMSO-treated cells. This pattern of expression was not maintained after fenretinide treatment; protein was localized to the nucleus, and sparse staining was seen along cytoplasmic extensions (Figure 4C). CALB2 staining was observed throughout the cytoplasm and along dendrites after fenretinide treatment; in the control dishes staining was less intense and perinuclear (Figure 4D). We then examined retinal cell- and retinal progenitor cell-associated markers. The expression of OPN1lw was increased after fenretinide treatment and was observed throughout the cell (Figure 4E). Rhodopsin protein was not observed in ARPE-19 under either condition (Figure 4F). The OPN4 antibody detected a nuclear signal in both treatment groups with punctate nuclear expression in control cells, which was more
intense after fenretinide treatment (Figure 4G). Pretreatment with the OPN4 blocking peptide blocked the signal (data not shown). TUBB3, a retinal cell-lineage marker found in early phase retinal cells (cones, horizontal, amacrine, and retinal ganglion cells), was sparsely distributed throughout the DMSO-treated cell cytoplasm, the staining intensity was increased after fenretinide treatment (Figure 4H). RCVRN was observed in a few control cells but was increased after fenretinide treatment; this was concurrent with a decrease in KRT8 expression (Figure 4I). PAX6 and CRX staining was detectable in the nucleus under both conditions but appeared more intense after fenretinide treatment (Figure 4J-K). Negative control dishes, where the primary antibody was omitted, produced no signal (Figure 4L). One consequence of treatment with fenretinide was a lower final density of cells in the dish at 7 days. By plating ARPE-19 cells at various densities and incubating in DMSO containing low-serum media only, we were able to demonstrate that the changes in ARPE-19 cell morphology and protein expression (CALB2) observed following fenretinide treatment were due to biochemical induction by fenretinide rather than differences in final cell density (Figure 4M).

NF-H expression was observed in control-DMSO-treated cells; however its expression varied. In the same dish we observed patches of cells with low and high levels of NF-H expression (Figure 5A). Fenretinide treatment increased levels of expression across the dish with strong staining along the cellular projections. Similarly, NF-M expression was also observed in a small percentage of control cells with increased levels of expression observed after 7 days treatment with fenretinide. To ascertain whether the expression of neuronal cell markers is a phenomenon specific to ARPE-19 cells in culture, we examined neuronal protein expression in cultured passage 2 human RPE cells and in the immortalized human
We observed strong cytosolic expression of NF-H in primary RPE and in approximately 50% of h1RPE7 cells. Similarly, synaptophysin expression was observed in both passage 2 RPE and h1RPE7 cells. The expression of neuronal markers NF-M/H was decreased in ARPE-19 cell by culture on PLC, a surface conducive to RPE cell differentiation [30] (Figure 5C). Culturing cells on PLC also prevented the fenretinide-induced increase of NF-M and NF-H in ARPE-19 cells.

Protein expression changes induced by fenretinide were examined in whole cell extracts by western blot analysis (Figure 6). A single band of the correct molecular weight was detected for each protein except for OPN4, where multiple bands were detected. In this instance we used a blocking
peptide to identify the specific band (Figure 7). Individual bands were analyzed by densitometry and quantified relative to a GAPDH loading control. Fenretinide induced a significant increase in the expression of CRX, OPN4, and CALB2 proteins (all p<0.05, Student t test) and a decrease in the expression of OPN3 and KRT8 (p<0.001 and p<0.01, respectively, Student t test). We found no significant difference in the expression of PAX6 or SOX2 by western blot following fenretinide treatment (p=0.476 and 0.180, respectively).

**DISCUSSION**

Previous studies have shown that the human RPE cell line, ARPE-19, is capable of developing neuronal cell-like characteristics following treatment with fenretinide. The phenotypic changes were accompanied by an increase in non-retinal specific neuronal cell markers. Given that ARPE-19 express neuronal cell markers after treatment with fenretinide, we have investigated the potential for transdifferentiation toward a retinal phenotype in this cell line by examining the expression of retinal-associated markers after fenretinide treatment.

Following 7 days of treatment with 3 μM fenretinide, cells were morphologically similar to neurons, with an elongated cell body and the formation of neurite branching. Confirming previous findings [26,28], we found that neuronal cell markers were upregulated in fenretinide-treated cells.

![Figure 4. Immunocytochemical analysis of neuronal and photoreceptor cell markers in ARPE-19 cells after treatment with dimethyl sulfoxide or fenretinide. A-K: ARPE-19 cells were treated with 3 μM fenretinide or DMSO and processed for immunocytochemistry. The nuclei of cells are stained with 4',6-diamidino-2-phenylindole (blue) with the exception of cells where protein expression was detected within the nucleus (OPN4, CRX, and PAX6). Staining is indicated by the text color. L: Staining was not detected in control plates where only secondary antibodies were used. M: Final cell density did not affect cell morphology or changes in protein expression. ARPE-19 cells were seeded at various densities (i, 0.5×10^3; ii, 1×10^3; and iii, 2×10^3 cells/dish) and cultured for 7 days in DMSO-containing medium before staining for CALB2 (red). All scale bars are 50 μm.](http://www.molvis.org/molvis/v17/a189)
Figure 5. Neuronal markers are expressed in retinal pigment epithelium cells in culture but are lost after culture on a porcine lens capsule membrane (PLC). The expression of neurofilament heavy and medium polypeptides (NF-H and NF-M respectively) varied in dimethyl sulfoxide (DMSO)-treated cells. A: The first two panels show the variation of NF-H expression within the same dish of DMSO-treated ARPE-19 cells, which is increased across the whole dish after fenretinide (FR) treatment. Similarly, the expression of NF-M varies within cells of the same field and is increased by fenretinide. B: Passage 2 primary human RPE cells and an additional human RPE cell line (h1RPE7) express the neuronal markers NF-H and synaptophysin (SYP). C: Culturing ARPE-19 on a PLC decreases the expression of neuronal markers in control cells and prevents the fenretinide-induced increase of neuronal markers. Protein staining is indicated by the color of the text (red or green). All scale bars equal 50 μm.
also found that DMSO-treated control ARPE-19 cells expressed many of the neuronal cell markers examined, such as SYP, NSE, NF-M, NF-H, CALB2, and TUBB3. Mammalian adult RPE cells have been shown to switch on TUBB3 within 5 days of primary culture and a multitude of neuronal progenitor and neuronal markers within 3 passages in culture [33,34]. ARPE-19 cells are a highly proliferative cell line that have lost several key RPE cell characteristics, including pigmentation, the typical RPE cell cobblestone-like morphology, junction formation [24], and many key RPE proteins critical to normal cell function [35,36]. Loss of phenotypic characteristics, such as enzyme activity and polarization, is not limited to the ARPE-19 cell line, it has also been demonstrated in the human D407 RPE cell line [37]. Although previous studies have shown that ARPE-19 cells express RPE65 mRNA transcripts [24,25], RPE65 protein has yet to be observed [36]. The loss of RPE cell markers and phenotype accompanied by expression of neuronal cell markers in RPE cells suggests that cells de-differentiate away from the fully differentiated RPE cell phenotype in culture.

Subsequent to retinal injury in amphibians, RPE cells re-enter the cell cycle and proliferate into de-differentiated cells, losing pigmentation and many RPE-specific genes, while gaining neuronal and retinal progenitor cell markers [38,39]. ARPE-19 cells appear to have undergone this initial transformation under normal culture conditions. We found that many genes involved in the differentiation of the neural retina are expressed in ARPE-19 cells, including Crx, a homeobox transcription factor expressed in developing and mature photoreceptor cells, which is required for photoreceptor differentiation. [40] and NRL, a leucine zipper transcription factor involved in the development of, and expressed predominantly in, rods [41]. These two transcription factors bind with the orphan nuclear receptor NR2E3 to regulate photoreceptor cell differentiation [42]. The presence of these factors in ARPE-19 cells under normal culture conditions suggest that they are predisposed toward a photoreceptor cell phenotype. Previous studies have shown that Crx is upregulated in human retinoblastoma cells after treatment with retinoids [43,44], and here we show that a synthetic retinoic acid also increases CRX gene and protein expression in human RPE cells.

ARPE-19 cells express several key transcription factors implicated in the maintenance of retinal progenitor cell multipotency, including PAX6 [45] and SOX2 [46]. PAX6, a master control transcription factor essential for normal development of the eye, is sufficient to induce proliferation, depigmentation, and neuronal gene expression in chick RPE cells [47]. PAX6 has been identified in transdifferentiating nonpigmented RPE [48], developing RPE [49], cultured adult RPE, and in human embryonic stem cell-derived RPE cells in vitro [35] but not in vivo [35,48]. The multipotency of
ARPE-19 is further implied by the expression of SOX2, a transcription factor associated with the proliferation of neural retina progenitor cells [46] and pluripotency [50,51]. Our findings, showing that PAX6 and SOX2 are present in ARPE-19 cells, suggest that these cells retain plasticity in terms of their capacity to differentiate.

While the expression of neuronal cell markers has previously been reported in ARPE-19 [28], these are the first data to demonstrate the presence of retinal cell-associated markers in a mammalian RPE cell line. Many of the retinal cell markers we examined are detectable under control conditions in ARPE-19 cells, including markers for photoreceptors, and neuroretinal cells, including retinal ganglion cells, amacrine cells, and retinal astrocytes. Importantly, fenretinide was able to induce the expression of the red cone opsin Opn1lw in ARPE-19 cells, which is the first report of such an occurrence in a mammalian RPE cell line; however we were unable to detect rhodopsin expression in either group. It is possible that fenretinide treatment does not induce the expression of rhodopsin in these cells, similar to findings after retinoic treatment in retinoblastoma cells by Li et al. [44]. We suggest that the retinoid treatment performed in the current study may be conducive to cone differentiation, while inhibiting rod gene expression. Alternatively, the lack of detectable rhodopsin may reflect a conserved developmental timing system where the differentiation of retinal cells in culture reflects that observed in vivo during development [52].

The RPE expresses many visual pigment-like proteins despite its apparent lack of light responsiveness. Our finding that melanopsin (OPN4) is expressed in ARPE-19 cells together with Opn1lw[lw is of significant interest as unlike the latter, melanopsin is a novel photopigment that shares a common ancestry with invertebrate rhabdomeric proteins [53]. Unlike the classic visual opsins, melanopsin is not thought to be expressed in rod and cone cells in the retina, instead its expression is restricted to networks of intrinsically photoreceptive retinal ganglion cells (ipRGCs) where it functions in nonimage-forming light responses [54-56]. Expression of melanopsin mRNA has previously been reported in the RPE cells of Xenopus [57], mouse [58], and humans; however for the latter it was suggested that this could be attributed to retinal contamination during dissection of tissues [59].

This is the first reporting of melanopsin expression in a human cell line; however immunoreactivity is confined to the nucleus, whereas it is localized throughout the cell membrane of ipRGCs in the rodent, primate, and human retina [56,60] and after overexpression in the human RPE cell line D407 [61]. Although melanopsin expression is increased by fenretinide in our cells staining for the RGC marker, BRN3 was not detected (data not shown). Previous findings have suggested that BRN3 is not required for the initial specification of RGCs, but it is needed for maturation of RGC cells [62]. The absence of BRN3 staining may reflect the transdifferentiation of cells toward an immature RGC, which might also explain the discrepancy in the localization of melanopsin. Alternatively, nuclear expression of melanopsin in the ARPE-19 cells line could indicate that the cells do not produce a mature form of the protein, which localizes to the plasma membrane [61]. Given these findings, the ARPE-19 cell line could prove to be a useful model for the study of melanopsin trafficking in human cells.

Other non-canonical opsins are also expressed outside of the photoreceptor cell layer of the retina. Human encephalopsin (Opn3) is a novel opsin of unknown function expressed in a wide range of non-neuronal tissues and the brain and retina [63]. In the eye it is present from early developmental stages to adulthood [64]. Here we show that encephalopsin is expressed in ARPE-19 cells and that both mRNA and protein levels are decreased after fenretinide treatment, which suggests that differentiation away from the epithelial cell type is not conducive to its expression. As yet Opn3 has not been identified in RPE cells in vivo.
Two of the non-canonical opsins, RRH and RGR opsin, are expressed in RPE cells in vivo. RRH retinal pigment epithelium-derived rhodopsin homolog (peropsin) is localized within the microvilli of RPE cells [65] where it is thought to act as a photoisomerase [66]. A previous study has shown that retinoic acid can delay the expression of RRH in ARPE-19 cells for up to 5 weeks [25]; however expression of the Rrh gene in our cells was unaffected by fenretinide treatment, which again suggests that either the synthetic retinoid may act on a different signaling pathway or that the passage number of ARPE-19 cells is a key factor in the regulation of some RPE-specific genes in culture. RGR opsin is a G protein-coupled receptor found in RPE and Muller cells [67] and acts as a photoisomerase, converting all-trans retinal to 11-cis retinal [68]. We were unable to detect Rgr mRNA expression in ARPE-19 cells. This absence, which has also been described previously [69], provides further evidence to suggest that ARPE-19 cells are in a de-differentiated state.

Recently, Samuel et al. identified a signaling pathway responsible for fenretinide-induced neuronal differentiation of ARPE-19 cells [70]. Fenretinide treatment was shown to activate the signaling kinases c-Raf and MEK1/2 in cells, while blocking MEK1/2 with inhibitors and small interference RNA (siRNA) prevented neuronal differentiation. The MEK pathway regulates many cellular processes, including proliferation and differentiation. Importantly, this pathway has also been implicated in the transdifferentiation of RPE to retina in vivo in adult newt *Xenopus* larvae and chick embryo [14,71,72].

The possibility of using transdifferentiated human RPE cells for the treatment of retinal disease is somewhat controversial. Clinical treatments for retinal degenerative diseases, resulting in the loss of photoreceptor cells, are extremely limited at present. Recently, there has been an increased interest in the development of cell-based therapies, which aim to either halt the progression of photoreceptor cell death or replace lost cells as a consequence of disease. To induce the transdifferentiation of a patient’s own RPE cells to form a fully functional retina, as observed in other species, would be an ideal solution to treat many forms of retinal degeneration. Although the transdifferentiation of mammalian RPE cells into retinal cells does not naturally occur in vivo, it might be possible to manipulate this process after retinal injury. It would therefore be interesting to view the effects of fenretinide treatment in the eye after retinal injury or in a degenerating animal model. The PLC will also provide a useful in vitro model system to study the effects of the microenvironment on fenretinide-induced transdifferentiation of RPE cells. Although not the natural substrate of RPE, the PLC could be used to provide clues as to the identity of signaling molecules required for, or the mechanisms preventing transdifferentiation of mammalian RPE in vitro and RPE cell differentiation in vivo in response to injury.

In this study we have demonstrated that in vitro ARPE-19 cells have the potential to differentiate toward a retinal cell lineage. At this stage it is unclear whether complete transdifferentiation, as specified by the formation of a fully functional cell, is a possibility. It is unlikely that the signals required for full transdifferentiation of cells are present in a tissue culture dish, and ultimately the local microenvironment of the damaged retina would be expected to play a key role in directing cell fate. A comparative analysis of the RPE response to retinal injury between species is imperative to identify the transdifferentiation signaling pathways absent in most vertebrates.

ACKNOWLEDGMENTS

The authors would like to thank Jenny McKenzie, Peter Munro and Robin Howes for technical advice and assistance. Our thanks are also extended to Dr. Astrid Limb for the supply of primary human RPE cells, to Profs. Jeremy Nathans and Robert Molday and Dr. Ignacio Provencio for kindly providing us with antibodies and antisera and to Tania Nolan for the design of Q-PCR reference gene primers. This work was supported by funding from Guide Dogs Ophthalmic Research project funding (Grant No. 2005–03b).

REFERENCES

1. Raymond SM, Jackson IJ. The retinal pigmented epithelium is required for development and maintenance of the mouse neural retina. Curr Biol 1995; 5:1286-95. [PMID: 8574586]
2. Saito T, Kaneko Y, Maruo F, Niino M, Sakaki Y. Study of the regenerating neural retina by electrophysiology and immunohistochemistry (bipolar- and cone-specific antigen localization). J Exp Zool 1994; 270:491-500. [PMID: 7798868]
3. Stone LS. The role of retinal pigment cells in regenerating neural retinae of adult salamander eyes. J Exp Zool 1950; 113:9.
4. Stone LS. Regeneration of neural retina and lens from retinal pigment cell grafts in adult newts. J Exp Zool 1957; 135:301-17. [PMID: 13481298]
5. Chiba C, Hoshino A, Nakamura K, Susaki K, Yamano Y, Kaneko Y, Kuwata O, Maruo F, Saito T. Visual cycle protein RPE65 persists in new retinal cells during retinal regeneration of adult newt. J Comp Neurol 2006; 495:391-407. [PMID: 16485283]
6. Yoshii C, Ueda Y, Okamoto M, Araki M. Neural retinal regeneration in the anuran amphibian Xenopus laevis post-metamorphosis: transdifferentiation of retinal pigmented epithelium regenerates the neural retina. Dev Biol 2007; 303:45-56. [PMID: 17184765]
7. Coulombre JL, Coulombre AJ. Regeneration of neural retina from the pigmented epithelium in the chick embryo. Dev Biol 1965; 12:79-92. [PMID: 5833111]
8. Stroeva OG. Experimental analysis of the eye morphogenesis in mammals. J Embryol Exp Morphol 1960; 8:349-68.
9. Zhao S, Thornquist SC, Barnstable CJ. In vitro transdifferentiation of embryonic rat retinal pigment
epithelium to neural retina. Brain Res 1995; 677:300-10. [PMID: 7552256]

10. Ma W, Yan RT, Xie W, Wang SZ. bHLH genes cath5 and cNSCL1 promote bFGF-stimulated RPE cells to transdifferentiate toward retinal ganglion cells. Dev Biol 2004; 265:320-8. [PMID: 14732395]

11. Sakaguchi DS, Janick LM, Reh TA. Basic fibroblast growth factor (FGF-2) induced transdifferentiation of retinal pigment epithelium: generation of retinal neurons and glia. Dev Dyn 1997; 209:387-98. [PMID: 9264262]

12. Fischer AJ, Reh TA. Transdifferentiation of pigmented epithelial cells: a source of retinal stem cells? Dev Neurosci 2001; 23:268-76. [PMID: 11756742]

13. Liang L, Yan RT, Ma W, Zhang H, Wang SZ. Exploring RPE as a source of photoreceptors: differentiation and integration of transdifferentiating cells grafted into embryonic chick eyes. Invest Ophthalmol Vis Sci 2006; 47:5066-74. [PMID: 17065528]

14. Susaki K, Chiba C. MEK mediates in vitro neural transdifferentiation of the adult newt retinal pigment epithelium cells: Is FGF2 an induction factor? Pigment Cell Res 2007; 20:364-79. [PMID: 17850510]

15. Yan RT, Ma WX, Wang SZ. neurogenin2 elicits the genesis of retinal neurons from cultures of nonneural cells. Proc Natl Acad Sci USA 2001; 98:15014-9. [PMID: 11752450]

16. Fuhrmann S, Levine EM, Reh TA. Extraocular mesenchyme patterns the optic vesicle during early eye development in the embryonic chick. Development 2000; 127:4599-609. [PMID: 11023863]

17. Sakami S, Etter P, Reh TA. Activin signaling limits the competence for retinal regeneration from the pigmented epithelium of transdifferentiating cells grafted into embryonic chick eyes. Invest Ophthalmol Vis Sci 2006; 47:5066-74. [PMID: 17065528]

18. Balkan W, Klintworth GK, Bock CB, Coffey P, Greenwood J. Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats. Proc Natl Acad Sci USA 2001; 98:9942-7. [PMID: 11504951]

19. Turowski P, Adamson P, Sathia J, Zhang JJ, Moss SE, Aylward GW, Hayes MJ, Kanuga N, Greenwood J. Basement membrane-dependent modification of phenotype and gene expression in human retinal pigment epithelial ARPE-19 cells. Invest Ophthalmol Vis Sci 2004; 45:2786-94. [PMID: 15277505]

20. Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003; 31:e73. [PMID: 12853650]

21. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophoton Int 2004; 11:36-42.

22. Vinores SA, Derevjanik NL, Mahlow J, Hackett SF, Haller JA, deJuan E, Frankfurter A, Campochiaro PA. Class III beta-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes. Exp Eye Res 1995; 60:385-400. [PMID: 8698076]

23. Janssen JJ, Kuhllmann ED, van Vugt AH, Winkens HJ, Janssen BP, Deutman AF, Driessen CA. Retinoic acid delays transcription of human retinal pigment neuroepithelium marker genes in ARPE-19 cells. Neuroreport 2000; 11:1571-9. [PMID: 10841379]

24. Chen S, Samuel W, Fariss RN, Duncan T, Kutty RK, Wiggert B. Differentiation of human retinal pigment epithelial cells into neuronal phenotype by N-(4-hydroxyphenyl)retinamide. J Neurochem 2003; 84:972-81. [PMID: 12603822]

25. Amemiya K, Haruta M, Takahashi M, Kosaka M, Eguchi G. Adult human retinal pigment epithelial cells capable of differentiating into neurons. Biochem Biophys Res Commun 2004; 316:1-5. [PMID: 15003502]

26. Chen S, Fariss RN, Kutty RK, Nelson R, Wiggert B. Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14–3–3, pax-6, tubulin beta-III, NSE, and bag-1 proteins. Mol Vis 2006; 12:1355-63. [PMID: 17110918]

27. Lund RD, Adamson P, Sauvé Y, Keegan DJ, Girman SV, Wang S, Winton H, Kanuga N, Kwan AS, Beauféne L, Zeribah A, Hetherington L, Couraud PO, Coffey P, Greenwood J. Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats. Proc Natl Acad Sci USA 2001; 98:9942-7. [PMID: 11504951]

28. Engelnardt M, Bogdahn U, Aigner L. Adult retinal pigment epithelial cells express neural progenitor properties and the neuronal precursor protein doublecortin. Brain Res 2005; 1040:98-111. [PMID: 15804431]

29. Vugler A, Carr AJ, Lawrence J, Chen LL, Burrell K, Wright A, Lundh P, Semo M, Ahmado A, Gias C, da Cruz L, Moore H, Andrews P, Walsh J, Coffey P. Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation. Exp Neurol 2008; 214:347-61. [PMID: 18926821]

30. Carr AJ, Vugler A, Lawrence J, Chen LL, Ahmado A, Chen FK, Semo M, Gias C, da Cruz L, Moore HD, Walsh J, Coffey PJ. Molecular characterization and functional analysis of phagocytosis by human embryonic stem cell-derived RPE cells using a novel human retinal assay. Mol Vis 2009; 15:283-95. [PMID: 19204785]

31. Davis AA, Bernstein PS, Bok D, Turner J, Nachtigal M, Hunt RC. A human retinal pigment epithelial cell line that retains
51. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-20. [PMID: 18029452]

52. Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, McMillan EL, Zhang SC, Gamm DM. Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci USA 2009; 106:16698-703. [PMID: 19706890]

53. Isoldi MC, Rollag MD, Castrucci AM, Provencio I. Rhodobacter phototransduction initiated by the vertebrate photopigment melanosin. Proc Natl Acad Sci USA 2005; 102:1217-21. [PMID: 15653769]

54. Ruby NF, Brennan TJ, Xie X, Cao V, Franken P, Heller HC, O'Hara BF. Role of melanosin in circadian responses to light. Science 2002; 298:2211-3. [PMID: 12481140]

55. Lucas RJ, Hattar S, Takao M, Berson DM, Foster RG, Yau KW. Diminished pupillary light reflex at high irradiances in melanosin-knockout mice. Science 2003; 299:245-7. [PMID: 12522249]

56. Ecker JL, Dumitrescu ON, Wong KY, Alam NM, Chen SK, LeGates T, Rema JM, Prusky GT, Berson DM, Hattar S. Melanosin-expressing retinal ganglion-cell photoreceptors: cellular diversity and role in pattern vision. Neuron 2010; 67:49-60. [PMID: 20624591]

57. Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD. Melanosin: An opsin in melanophores, brain, and eye. Proc Natl Acad Sci USA 1998; 95:340-5. [PMID: 9419377]

58. Peirson SN, Bovee-Geurts PH, Lusi D, Jeffery G, DeGrip WJ, Foster RG. Expression of the candidate circadian photopigment melanosin (Opn4) in the mouse retinal pigment epithelium. Brain Res Mol Brain Res 2004; 123:132-5. [PMID: 15046875]

59. Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD. A novel human opsin in the inner retina. J Neurosci 2000; 20:600-5. [PMID: 10632589]

60. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanosin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 2002; 295:1065-70. [PMID: 11834834]

61. Giesbers BE, Shirzad-Wasei N, Bosman GJ, de Grip WJ. Functional expression, targeting and Ca2+ signaling of a mouse melanosin-eYFP fusion protein in a retinal pigment epithelium cell line. Photochem Photobiol 2008; 84:990-5. [PMID: 18422879]

62. Gan J, Wang SW, Huang Z, Klein WH. POU domain factor Bmn-3b is essential for retinal ganglion cell differentiation and survival but not for initial cell fate specification. Dev Biol 1999; 210:469-80. [PMID: 10357904]

63. Halford S, Freedman MS, Bellingham J, Inglis SL, Poopalasundaram S, Soni BG, Foster RG, Hunt DM. Characterization of a novel human opsin gene with wide tissue expression and identification of embedded and flanking genes on chromosome 1q43. Genomics 2001; 72:203-8. [PMID: 11694879]

64. Hennig AK, Peng GH, Chen S. Regulation of photoreceptor gene expression by Crx-associated transcription factor network. Brain Res 2008; 1192:114-33. [PMID: 17662965]

65. Boaitright JH, Stodulkova E, Do VT, Padove SA, Nguyen HT, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 134:959-68. [PMID: 17579794]

66. Arreata E, Bernardini S, Bernardini E, Filoni S, Cannata SM. Pigmented epithelium to retinal transdifferentiation and Pax6 expression in larval Xenopus laevis. J Exp Zool A Comp. Exp Biol 2005; 303:958-67. [PMID: 16217804]

67. Azuma N, Tadokoro K, Asaka A, Yamada M, Yamaguchi Y, Hutton SR, Pevny LH. SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev 2006; 20:1187-202. [PMID: 16651659]

68. Al A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44:996-1007. [PMID: 12601020]

69. Marquardt T, Ashery-Padan R, Andrejewski N, Scardigli R, Guillemot F, Gruss P. Pax6 is required for the multipotent state of retinal progenitor cells. Cell 2001; 105:43-55. [PMID: 11301001]

70. Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH. SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev 2006; 20:1187-202. [PMID: 16651659]

71. Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD. Melanosin: An opsin in melanophores, brain, and eye. Proc Natl Acad Sci USA 1998; 95:340-5. [PMID: 9419377]

72. Giesbers BE, Shirzad-Wasei N, Bosman GJ, de Grip WJ. Functional expression, targeting and Ca2+ signaling of a mouse melanosin-eYFP fusion protein in a retinal pigment epithelium cell line. Photochem Photobiol 2008; 84:990-5. [PMID: 18422879]

73. Gan J, Wang SW, Huang Z, Klein WH. POU domain factor Bmn-3b is essential for retinal ganglion cell differentiation and survival but not for initial cell fate specification. Dev Biol 1999; 210:469-80. [PMID: 10357904]

74. Halford S, Freedman MS, Bellingham J, Inglis SL, Poopalasundaram S, Soni BG, Foster RG, Hunt DM. Characterization of a novel human opsin gene with wide tissue expression and identification of embedded and flanking genes on chromosome 1q43. Genomics 2001; 72:203-8. [PMID: 11694879]
66. Koyanagi M, Terakita A, Kubokawa K, Shichida Y. Amphioxus homologs of Go-coupled rhodopsin and peropsin having 11-cis- and all-trans-retinals as their chromophores. FEBS Lett 2002; 531:525-8. [PMID: 12435605]

67. Jiang M, Pandey S, Fong HK. An opsin homologue in the retina and pigment epithelium. Invest Ophthalmol Vis Sci 1993; 34:3669-78. [PMID: 8258527]

68. Hao W, Fong HK. The endogenous chromophore of retinal G protein-coupled receptor opsin from the pigment epithelium. J Biol Chem 1999; 274:6085-90. [PMID: 10037690]

69. Yang M, Wang XG, Stout JT, Chen P, Hjelmeland LM, Appukuttan B, Fong HK. Expression of a recombinant human RGR opsin in Lentivirus-transduced cultured cells. Mol Vis 2000; 6:237-42. [PMID: 11086144]

70. Samuel W, Kutty RK, Sekhar S, Vijayasarathy C, Wiggert B, Redmond TM. Mitogen-activated protein kinase pathway mediates N-(4-hydroxyphenyl)retinamide-induced neuronal differentiation in the ARPE-19 human retinal pigment epithelial cell line. J Neurochem 2008; 106:591-602. [PMID: 18410500]

71. Galy A, Neron B, Planque N, Saule S, Eychene A. Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina. Dev Biol 2002; 248:251-64. [PMID: 12167402]

72. Vergara MN, Del Rio-Tsonis K. Retinal regeneration in the Xenopus laevis tadpole: a new model system. Mol Vis 2009; 15:1000-13. [PMID: 19461929]

73. Peng GH, Chen S. Crx activates opsin transcription by recruiting HAT-containing co-activators and promoting histone acetylation. Hum Mol Genet 2007; 16:2433-52. [PMID: 17656371]